Trial Profile
Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating DA-3031 (PEG-G-CSF) to Filgrastim (Dong-A) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Dong-A Pharmaceutical
- 12 May 2014 New trial record